About Peptide Insider

The problem we are trying to solve

Search for almost any peptide and you will find two kinds of page. One kind sells something and treats animal studies as though they were clinical proof. The other is a research paper written for specialists. There is very little in between: nothing that takes the published record seriously and still explains it to someone who does not already know what a surrogate endpoint is.

That gap is where the misinformation in this field lives. A rodent tendon study becomes “BPC-157 heals injuries”. A Phase 1 hormone measurement becomes “CJC-1295 works”. A drug approved for one narrow indication becomes a general-purpose recommendation. None of those transformations require anyone to lie — they only require the intermediate steps to go unmentioned.

What we do differently

Four things, consistently:

• We grade the evidence and publish the criteria. Every compound carries one of five evidence labels, and the full definitions — including what each label explicitly does not mean — are public.
• We grade research areas separately. A compound can have real human trial evidence in one context and none at all in another. Collapsing that into a single rating hides the most important thing on the page.
• We cite primary sources. Regulatory documents, trial registrations and peer-reviewed literature, linked directly, in preference to secondary summaries.
• We say when something is unknown. Every profile has a section for risks that have not been studied. On unapproved compounds it is usually the longest section, and we do not treat that as a gap to be filled with reassurance.

What we do not do

• We do not provide medical advice, dosing, protocols or administration guidance.
• We do not invent authors, reviewers, credentials, studies or citations.
• We do not claim to have laboratory-tested any product. If we ever do commission testing, we will say so and publish the results and the methodology.
• We do not let commercial relationships influence editorial conclusions, and we disclose them where they exist rather than only in the footer.

Where the site is today

Peptide Insider currently publishes 10 compound profiles and 13 articles. That is a deliberate starting point rather than a limitation: we would rather publish a small number of pages that hold up than a large number that do not. The library grows as profiles are researched and verified, not as slots are filled.

Who writes this

Peptide Insider Editorial Team. We have deliberately not invented physicians or medical reviewers to appear on bylines — a fabricated credential on a health site is worse than an honest absence of one. The publishing system is built so that named expert reviewers can be added to individual pages as they join, and reviewer credits will appear on the pages they actually reviewed.

Corrections

If something on this site is wrong, we want to know and we will fix it. Our editorial policy sets out how corrections are handled and how updates are recorded. Write to us through the contact page.